Terms: = Ovarian epithelial cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Clinical Outcome
21 results:
1. Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and ovarian cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?
Infante M; Arranz-Ledo M; Lastra E; Abella LE; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232793
[TBL] [Abstract] [Full Text] [Related]
2.
Liontos M; Zografos E; Zoumpourlis P; Andrikopoulou A; Svarna A; Fiste O; Kunadis E; Papatheodoridi AM; Kaparelou M; Koutsoukos K; Thomakos N; Haidopoulos D; Rodolakis A; Dimopoulos MA; Zagouri F
Curr Oncol; 2021 Nov; 28(6):4446-4456. PubMed ID: 34898566
[TBL] [Abstract] [Full Text] [Related]
3. brca1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer.
Elazezy M; Prieske K; Kluwe L; Oliveira-Ferrer L; Peine S; Müller V; Woelber L; Schmalfeldt B; Pantel K; Joosse SA
Mol Oncol; 2021 Dec; 15(12):3615-3625. PubMed ID: 34601813
[TBL] [Abstract] [Full Text] [Related]
4. clinical outcome in patients with primary epithelial ovarian cancer and germline brca1/2-mutation - real life data.
Ataseven B; Tripon D; Schwameis R; Harter P; Rhiem K; Schneider S; Heikaus S; Baert T; Francesco AP; Heitz F; Traut A; Groeben HT; Schmutzler R; du Bois A
Gynecol Oncol; 2021 Dec; 163(3):569-577. PubMed ID: 34565600
[TBL] [Abstract] [Full Text] [Related]
5. Germline and Somatic brca1/2 Gene Mutational Status and clinical outcomes in epithelial Peritoneal, ovarian, and Fallopian Tube cancer: Over a Decade of Experience in a Single Institution in Korea.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
Cancer Res Treat; 2020 Oct; 52(4):1229-1241. PubMed ID: 32718143
[TBL] [Abstract] [Full Text] [Related]
6. In silico analysis of DYNLL1 expression in ovarian cancer chemoresistance.
Berkel C; Cacan E
Cell Biol Int; 2020 Aug; 44(8):1598-1605. PubMed ID: 32208526
[TBL] [Abstract] [Full Text] [Related]
7. Salvage lymphadenectomy in recurrent ovarian cancer patients: Analysis of clinical outcome and brca1/2 gene mutational status.
Gallotta V; Bruno M; Conte C; Giudice MT; Davià F; Moro F; Zannoni GF; Fagotti A; De Bonis M; Capoluongo E; Scambia G; Ferrandina G
Eur J Surg Oncol; 2020 Jul; 46(7):1327-1333. PubMed ID: 32085925
[TBL] [Abstract] [Full Text] [Related]
8. Genetic Versus Epigenetic brca1 Silencing Pathways: clinical Effects in Primary ovarian cancer Patients: A Study of the Tumor Bank ovarian cancer Consortium.
Sun T; Ruscito I; Dimitrova D; Chekerov R; Kulbe H; Baron U; Blanchard V; Panici PB; Darb-Esfahani S; Sehouli J; Olek S; Braicu EI
Int J Gynecol Cancer; 2017 Oct; 27(8):1658-1665. PubMed ID: 28691938
[TBL] [Abstract] [Full Text] [Related]
9. Germline mutations of brca1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank ovarian cancer (TOC) Consortium.
Dimitrova D; Ruscito I; Olek S; Richter R; Hellwag A; Türbachova I; Woopen H; Baron U; Braicu EI; Sehouli J
Tumour Biol; 2016 Sep; 37(9):12329-12337. PubMed ID: 27297669
[TBL] [Abstract] [Full Text] [Related]
10. Downregulation of the cancer susceptibility protein WRAP53β in epithelial ovarian cancer leads to defective DNA repair and poor clinical outcome.
Hedström E; Pederiva C; Farnebo J; Nodin B; Jirström K; Brennan DJ; Farnebo M
Cell Death Dis; 2015 Oct; 6(10):e1892. PubMed ID: 26426684
[TBL] [Abstract] [Full Text] [Related]
11. RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancer.
Häfner N; Steinbach D; Jansen L; Diebolder H; Dürst M; Runnebaum IB
Int J Cancer; 2016 Jan; 138(1):217-28. PubMed ID: 26175272
[TBL] [Abstract] [Full Text] [Related]
12. Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas.
Uehara Y; Oda K; Ikeda Y; Koso T; Tsuji S; Yamamoto S; Asada K; Sone K; Kurikawa R; Makii C; Hagiwara O; Tanikawa M; Maeda D; Hasegawa K; Nakagawa S; Wada-Hiraike O; Kawana K; Fukayama M; Fujiwara K; Yano T; Osuga Y; Fujii T; Aburatani H
PLoS One; 2015; 10(6):e0128066. PubMed ID: 26043110
[TBL] [Abstract] [Full Text] [Related]
13. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
; Hollestelle A; van der Baan FH; Berchuck A; Johnatty SE; Aben KK; Agnarsson BA; Aittomäki K; Alducci E; Andrulis IL; Anton-Culver H; Antonenkova NN; Antoniou AC; Apicella C; Arndt V; Arnold N; Arun BK; Arver B; Ashworth A; ; Baglietto L; Balleine R; Bandera EV; Barrowdale D; Bean YT; Beckmann L; Beckmann MW; Benitez J; Berger A; Berger R; Beuselinck B; Bisogna M; Bjorge L; Blomqvist C; Bogdanova NV; Bojesen A; Bojesen SE; Bolla MK; Bonanni B; Brand JS; Brauch H; ; Brenner H; Brinton L; Brooks-Wilson A; Bruinsma F; Brunet J; Brüning T; Budzilowska A; Bunker CH; Burwinkel B; Butzow R; Buys SS; Caligo MA; Campbell I; Carter J; Chang-Claude J; Chanock SJ; Claes KBM; Collée JM; Cook LS; Couch FJ; Cox A; Cramer D; Cross SS; Cunningham JM; Cybulski C; Czene K; Damiola F; Dansonka-Mieszkowska A; Darabi H; de la Hoya M; deFazio A; Dennis J; Devilee P; Dicks EM; Diez O; Doherty JA; Domchek SM; Dorfling CM; Dörk T; Silva IDS; du Bois A; Dumont M; Dunning AM; Duran M; Easton DF; Eccles D; Edwards RP; Ehrencrona H; Ejlertsen B; Ekici AB; Ellis SD; ; Engel C; Eriksson M; Fasching PA; Feliubadalo L; Figueroa J; Flesch-Janys D; Fletcher O; Fontaine A; Fortuzzi S; Fostira F; Fridley BL; Friebel T; Friedman E; Friel G; Frost D; Garber J; García-Closas M; Gayther SA; ; ; Gentry-Maharaj A; Gerdes AM; Giles GG; Glasspool R; Glendon G; Godwin AK; Goodman MT; Gore M; Greene MH; Grip M; Gronwald J; Gschwantler Kaulich D; Guénel P; Guzman SR; Haeberle L; Haiman CA; Hall P; Halverson SL; Hamann U; Hansen TVO; Harter P; Hartikainen JM; Healey S; ; Hein A; Heitz F; Henderson BE; Herzog J; T Hildebrandt MA; Høgdall CK; Høgdall E; Hogervorst FBL; Hopper JL; Humphreys K; Huzarski T; Imyanitov EN; Isaacs C; Jakubowska A; Janavicius R; Jaworska K; Jensen A; Jensen UB; Johnson N; Jukkola-Vuorinen A; Kabisch M; Karlan BY; Kataja V; Kauff N; ; Kelemen LE; Kerin MJ; Kiemeney LA; Kjaer SK; Knight JA; Knol-Bout JP; Konstantopoulou I; Kosma VM; Krakstad C; Kristensen V; Kuchenbaecker KB; Kupryjanczyk J; Laitman Y; Lambrechts D; Lambrechts S; Larson MC; Lasa A; Laurent-Puig P; Lazaro C; Le ND; Le Marchand L; Leminen A; Lester J; Levine DA; Li J; Liang D; Lindblom A; Lindor N; Lissowska J; Long J; Lu KH; Lubinski J; Lundvall L; Lurie G; Mai PL; Mannermaa A; Margolin S; Mariette F; Marme F; Martens JWM; Massuger LFAG; Maugard C; Mazoyer S; McGuffog L; McGuire V; McLean C; McNeish I; Meindl A; Menegaux F; Menéndez P; Menkiszak J; Menon U; Mensenkamp AR; Miller N; Milne RL; Modugno F; Montagna M; Moysich KB; Müller H; Mulligan AM; Muranen TA; Narod SA; Nathanson KL; Ness RB; Neuhausen SL; Nevanlinna H; Neven P; Nielsen FC; Nielsen SF; Nordestgaard BG; Nussbaum RL; Odunsi K; Offit K; Olah E; Olopade OI; Olson JE; Olson SH; Oosterwijk JC; Orlow I; Orr N; Orsulic S; Osorio A; Ottini L; Paul J; Pearce CL; Pedersen IS; Peissel B; Pejovic T; Pelttari LM; Perkins J; Permuth-Wey J; Peterlongo P; Peto J; Phelan CM; Phillips KA; Piedmonte M; Pike MC; Platte R; Plisiecka-Halasa J; Poole EM; Poppe B; Pylkäs K; Radice P; Ramus SJ; Rebbeck TR; Reed MWR; Rennert G; Risch HA; Robson M; Rodriguez GC; Romero A; Rossing MA; Rothstein JH; Rudolph A; Runnebaum I; Salani R; Salvesen HB; Sawyer EJ; Schildkraut JM; Schmidt MK; Schmutzler RK; Schneeweiss A; Schoemaker MJ; Schrauder MG; Schumacher F; Schwaab I; Scuvera G; Sellers TA; Severi G; Seynaeve CM; Shah M; Shrubsole M; Siddiqui N; Sieh W; Simard J; Singer CF; Sinilnikova OM; Smeets D; Sohn C; Soller M; Song H; Soucy P; Southey MC; Stegmaier C; Stoppa-Lyonnet D; Sucheston L; ; Swerdlow A; Tangen IL; Tea MK; Teixeira MR; Terry KL; Terry MB; Thomassen M; Thompson PJ; Tihomirova L; Tischkowitz M; Toland AE; Tollenaar RAEM; Tomlinson I; Torres D; Truong T; Tsimiklis H; Tung N; Tworoger SS; Tyrer JP; Vachon CM; Van 't Veer LJ; van Altena AM; Van Asperen CJ; van den Berg D; van den Ouweland AMW; van Doorn HC; Van Nieuwenhuysen E; van Rensburg EJ; Vergote I; Verhoef S; Vierkant RA; Vijai J; Vitonis AF; von Wachenfeldt A; Walsh C; Wang Q; Wang-Gohrke S; Wappenschmidt B; Weischer M; Weitzel JN; Weltens C; Wentzensen N; Whittemore AS; Wilkens LR; Winqvist R; Wu AH; Wu X; Yang HP; Zaffaroni D; Pilar Zamora M; Zheng W; Ziogas A; Chenevix-Trench G; Pharoah PDP; Rookus MA; Hooning MJ; Goode EL
Gynecol Oncol; 2016 May; 141(2):386-401. PubMed ID: 25940428
[TBL] [Abstract] [Full Text] [Related]
14. brca1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.
Lesnock JL; Darcy KM; Tian C; Deloia JA; Thrall MM; Zahn C; Armstrong DK; Birrer MJ; Krivak TC
Br J Cancer; 2013 Apr; 108(6):1231-7. PubMed ID: 23462720
[TBL] [Abstract] [Full Text] [Related]
15. Phenotypic characterization of hereditary epithelial ovarian cancer based on a tissue microarray study.
Muñoz-Repeto I; García MJ; Kamieniak M; Ramón Y Cajal T; Domingo S; Cazorla A; García Donas J; Hernando Polo S; García Sagredo JM; Hernández E; Lacambra C; Saez R; Robles L; Borrego S; Prat J; Palacios J; Benítez J
Histol Histopathol; 2013 Jan; 28(1):133-44. PubMed ID: 23233066
[TBL] [Abstract] [Full Text] [Related]
16. brca1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer.
Carser JE; Quinn JE; Michie CO; O'Brien EJ; McCluggage WG; Maxwell P; Lamers E; Lioe TF; Williams AR; Kennedy RD; Gourley C; Harkin DP
Gynecol Oncol; 2011 Dec; 123(3):492-8. PubMed ID: 21920589
[TBL] [Abstract] [Full Text] [Related]
17. Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker.
Kamat AA; Baldwin M; Urbauer D; Dang D; Han LY; Godwin A; Karlan BY; Simpson JL; Gershenson DM; Coleman RL; Bischoff FZ; Sood AK
Cancer; 2010 Apr; 116(8):1918-25. PubMed ID: 20166213
[TBL] [Abstract] [Full Text] [Related]
18. Impact of androgen receptor cytosine-adenine-guanine polymorphisms on clinical outcome in BRCA mutation-associated epithelial ovarian cancers.
Li AJ; McAllister P; Karlan BY
Gynecol Oncol; 2010 Jan; 116(1):105-8. PubMed ID: 19818997
[TBL] [Abstract] [Full Text] [Related]
19. Hereditary ovarian cancer.
Prat J; Ribé A; Gallardo A
Hum Pathol; 2005 Aug; 36(8):861-70. PubMed ID: 16112002
[TBL] [Abstract] [Full Text] [Related]
20. Survival in familial, brca1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for cancer Research (UKCCCR) Familial ovarian cancer Study Group.
Pharoah PD; Easton DF; Stockton DL; Gayther S; Ponder BA
Cancer Res; 1999 Feb; 59(4):868-71. PubMed ID: 10029077
[TBL] [Abstract] [Full Text] [Related]
[Next]
